Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma
LenHAP might offer enhanced clinical benefits over BevHAP in uHCC, particularly for PotenR patients, while maintaining equivalent tolerability.
Authors
- Min-qiang Lu (ORCID: https://orcid.org/0000-0002-5030-8666)
- QiJiong Li (ORCID: https://orcid.org/0000-0002-3149-1645)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- ZhiCheng Lai (ORCID: https://orcid.org/0000-0003-4109-9468)
- Li Xu (ORCID: https://orcid.org/0000-0001-6883-6590)
- Ming Shi (ORCID: https://orcid.org/0000-0002-4051-4474)
- Yujie Xu (ORCID: https://orcid.org/0000-0002-8941-2479)
- Wei Wei (ORCID: https://orcid.org/0000-0001-5929-7409)
- Na Liu (ORCID: https://orcid.org/0000-0002-5644-3631)
- Hailong Chen (ORCID: https://orcid.org/0000-0001-9731-824X)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6116-5015)
- Zichao Wu (ORCID: https://orcid.org/0000-0003-2858-4856)
- Lichang Huang
Institutions
- Sun Yat-sen University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou First People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1573098
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangzhou First People's Hospital
- National Key Research and Development Program of China